Glp-1 Analogues 市場規模, シェア, 製品(Ozempic, Trulicity, Mounjaro, Xultophy, Victoza, Saxenda, その他), ドラッグクラス(Semaglutide, Dulaglutide, Liraglutide, Exenatide), 管理のルート(Parenteral, Oral), 流通チャネル(病院薬局, 小売薬局, およびOnlinecies), 傾向分析まで 2034 および予測 - 2034

Product Development:

• Besides that, product development can further produce huge growth opportunities for companies operating in GLP-1 analogues. The convenience in dosage forms will turn out to be a key to better compliance and access for patients. Combining GLP-1 analogues with other anti-diabetic or weight loss drugs can develop combination therapies with higher therapeutic benefits. In addition, increasing its adoption among patients by reducing the injection frequency can be done by developing long-acting formulations, which prolong the action through a once-a-week or once-a-month dos.